Adaptimmune Therapeutics plc (ADAPY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4 | 6 | 27 | 60 | 178 | 6 | - | - |
| Operating profit | $m | -73 | - | ||||||
| Net profit | $m | -130 | -158 | -165 | -114 | -71 | 25 | - | - |
| EPS reported | $ | -0.30 | - | ||||||
| Operating cashflow per share | $ | 0.00 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | 0.00 | - | ||||||
| Free cash flow | $m | - | - | ||||||
| Net debt | $m | -26 | - | ||||||
| Book value equity | $m | 32 | - | ||||||
| Book value per share | $ | 0.12 | - | ||||||
| Number of shares | m | 272.41 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.07 | - | ||||||
| P/S LTM | x | 0.37 | - | ||||||
| P/FCF LTM | x | 0.00 | - | ||||||
| EV/EBITDA LTM | x | 0.17 | - | ||||||
| EV/Sales LTM | x | -1.63 | - | ||||||
| Earnings Yield LTM | % | +11.54% | - | ||||||
| FCF Yield | % | 0.00% | - | ||||||
| Quality | |||||||||
| ROE | % | +78.85% | - | ||||||
| ROIC | % | -1.58% | - | ||||||
| Operating margin | % | -12.25% | - | ||||||
| Gross margin | % | +100.00% | - | ||||||
| FCF/Sales | % | 0.00% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -96.67% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.21 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -0.81 | - | ||||||
| Gross debt/equity | x | 0.44 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Adaptimmune Therapeutics plc (ADAPY)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free